Table 4. Prevalence of immunosuppressive conditions by person age and sex for acute respiratory illness in the MarketScan database, United States, July 2012–August 2017.
| Characteristic | All enrollees, person-years, no. (%)* | Immunosuppressive conditions† |
|
|---|---|---|---|
| Person-years (%) | Prevalence/100 person-years, % | ||
| Total |
115,113,322 (100) |
6,823,509 (100) |
5.9 |
| Age, y | |||
| <1–8 | 11,074,106 (10) | 160,137 (2) | 1.4 |
| 9–17 | 13,666,230 (12) | 474,703 (7) | 3.5 |
| 18–49 | 52,413,795 (46) | 2,580,737 (38) | 4.9 |
| 50–64 | 28,552,259 (25) | 2,470,817 (36) | 8. |
|
>65 |
9,406,932 (8) |
1,137,115 (17) |
12.1 |
| Sex | |||
| M | 55,282,285 (48) | 2,597,852 (38) | 4.7 |
| F | 59,831,037 (52) | 4,225,657 (62) | 7.1 |
*Person-time was calculated by using the total months each enrollee spent in a health plan supplying data to MarketScan during the study period. During August 2012–July 2017, a total of 47.2 million unique enrollees were in our MarketScan analysis. †See Figure 1. Denotes patients had International Classification of Diseases codes for either 3 immunosuppressive conditions OR 3 conditions + immunosuppressive pharmacologic treatment (chemotherapeutic agents or immune-modeling agents or systemic corticosteroids >14 d).